[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342644-105":59,"doc-detail-342644-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","harnessing-innate-immune-pathways-for-therapeutic-advancement-in-cancer","Harnessing innate immune pathways for therapeutic advancement in cancer","","Innate immune pathway signaling is increasingly central to cancer therapy, acting across immune and non-immune cell types to reshape the tumor microenvironment and improve outcomes in preclinical models. Despite this promise, clinical translation of pathway-targeting agonists has been limited, and activation can even paradoxically accelerate tumor progression. The review analyzes this therapeutic uncertainty by highlighting heterogeneity shaped by tumor developmental stage, pathway status, and specific cell types. It proposes multidimensional diversity within the TME and links pro-tumor effects to suppression of classical routes and engagement of alternative pro-tumor networks, guiding more precise targeting strategies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/harnessing-innate-immune-pathways-for-therapeutic-advancement-in-cancer/342644/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/harnessing-innate-immune-pathways-for-therapeutic-advancement-in-cancer/342644.png","ImageObject",300,407,{"name":92,"@type":93},"Olivia Brown","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is targeting innate immune pathways considered promising in cancer therapy?","Question",{"text":112,"@type":113},"Agonists can reshape the tumor microenvironment and improve prognosis in preclinical studies, and the pathway acts broadly across multiple cell types beyond innate immune cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What limits the clinical success of drugs targeting innate immune pathways?",{"text":117,"@type":113},"Clinical effectiveness remains limited, and activation of the innate immune pathway can paradoxically promote tumor progression, creating uncertainty about therapeutic benefit.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the review explain the heterogeneity of innate immune pathway roles in tumors?",{"text":121,"@type":113},"The review links pathway behavior to tumor development stage, pathway status, and specific cell types, proposing multidimensional diversity reflected in varied signaling networks within the tumor microenvironment.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342644,1791203348,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":29,"preview_urls":146},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Signal Transduction [and Targeted Therapy](and Targeted Therapy www.nature.com/sigtrans)[ www.nature.com/sigtrans](and Targeted Therapy www.nature.com/sigtrans)  \nREVIEW ARTICLE  \nOPEN  \nHarnessing innate immune pathways for therapeutic advancement in cancer  \nAnkang Hu 1,2,3,4,5, Li Sun1,3,4,5, Hao Lin1,3,4,5, Yuheng Liao6, Hui Yang 1,2,3,4,5 ✉ and Ying Mao 1,3,4,5 ✉  \n\n| | The innate immune pathway is receiving increasing attention in cancer therapy. This pathway is ubiquitous across various cell types, not only in innate immune cells but also in adaptive immune cells, tumor cells, and stromal cells. Agonists targeting the innate immune pathway have shown profound changes in the tumor microenvironment (TME) and improved tumor prognosis in preclinical studies. However, to date, the clinical success of drugs targeting the innate immune pathway remains limited. Interestingly, recent studies have shown that activation of the innate immune pathway can paradoxically promote tumor progression. The uncertainty surrounding the therapeutic effectiveness of targeted drugs for the innate immune pathway is a critical issue that needs immediate investigation. In this review, we observe that the role of the innate immune pathway demonstrates heterogeneity, linked to the tumor development stage, pathway status, and speciﬁc cell types. We propose that within the TME, the innate immune pathway exhibits multidimensional diversity. This diversity is fundamentally rooted in cellular heterogeneity and is manifested as a variety of signaling networks. The pro-tumor effect of innate immune pathway activation essentially reﬂects the suppression of classical pathways and the activation of potential pro-tumor alternative pathways. Reﬁning our understanding of the tumor’s innate immune pathway network and employing appropriate targeting strategies can enhance our ability to harness the anti-tumor potential of the innate immune pathway and ultimately bridge the gap from preclinical to | |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  | clinical application. |  |\n|  |  |  |\n|  |  |  |\n|  | Signal Transduction and Targeted Therapy (2024)9:68 ; [https://doi.org/10.1038/s41392-024-01765-9](https://doi.org/10.1038/s41392-024-01765-9) |  |\n|  |  |  |\n\nINTRODUCTION  \nThe emergence of immunotherapy has revolutionized the paradigm of cancer treatment with immune checkpoint blockers (ICB) . These monoclonal antibodies, blocking immune checkpointrelevant molecules such as PD1, PD-L1, and CTLA-4, exert their effect by inhibiting the immunosuppressive signals in T cells, thus amplifying T cell-mediated tumor cytotoxicity. While the utility of ICB has ushered in positive outcomes across multiple cancer treatments, their effectiveness largely hinges on the presence of cytotoxic T cells capable of eradicating cancer cells within the tumor.1 Unfortunately, not all tumors boast an adequate presence of these potent cells for effective regression. Based on immune characteristics, tumors are classiﬁed into four main categories —hot, altered-excluded, altered-immunosuppressed, and cold, representing high T cell inﬁltration, T cell peripheral inﬁltration without tumor invasion, T cell inﬁltration with immunosuppression, and lack of T cell inﬁltration, respectively. Compared to hot tumors, cold tumors inherently lack T cell inﬁltration, and tumors with altered phenotypes cannot harness T cell functionality due to spatial or functional constraints.2 For cold tumors, such as glioblastomas and pancreatic cancer, ICB has not yielded  \nsigniﬁcant breakthroughs.3,4 Improving outcomes for patients with these types of tumors remains an urgent challenge.  \nThe innate immusne pathway, an integral component of the immune system, plays a pivotal role in immune system activation. A hallmark of the innate immune response is its “broad” scope. This is evident in its widespr","cbCaikT5YoIwwM2h","https://ap.wps.com/l/cbCaikT5YoIwwM2h","pdf",7916755,59,"English","# Introduction\n# Innate immune pathway in cancer immunotherapy\n# Therapeutic promise and clinical limitations\n# Heterogeneity and pro-tumor mechanisms\n# Targeting strategies and translational outlook","[{\"question\":\"Why is targeting innate immune pathways considered promising in cancer therapy?\",\"answer\":\"Agonists can reshape the tumor microenvironment and improve prognosis in preclinical studies, and the pathway acts broadly across multiple cell types beyond innate immune cells.\"},{\"question\":\"What limits the clinical success of drugs targeting innate immune pathways?\",\"answer\":\"Clinical effectiveness remains limited, and activation of the innate immune pathway can paradoxically promote tumor progression, creating uncertainty about therapeutic benefit.\"},{\"question\":\"How does the review explain the heterogeneity of innate immune pathway roles in tumors?\",\"answer\":\"The review links pathway behavior to tumor development stage, pathway status, and specific cell types, proposing multidimensional diversity reflected in varied signaling networks within the tumor microenvironment.\"}]","Harnessing innate immune pathways for therapeutic advancement in cancer | PDF",1790047534,149,[147,151,155,159,163,167],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f08d74312c71216cbd8b51d969fd6740.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/23228d6673a82efdc46a82e5471bab84.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9c1b0e17cdabe422de751996c06a7338.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3835ab07a5e386514b7abc926aba5af8.webp",980,1301,{"page_no":24,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0b18543208a440360236e2097976f761.webp",979,1300,{"page_no":29,"url":168,"width":169,"height":170},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dc7066e24c8936d392b47b1e52a9e948.webp",978,1299]